Pardoprunox

From Self-sufficiency
Jump to: navigation, search
Pardoprunox
150px
Systematic (IUPAC) name
7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 269718-84-5
ATC code none
PubChem CID 6918524
ChemSpider 5293721
Chemical data
Formula C12H15N3O2
Molar mass 269.73 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pardoprunox (SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson's disease and as of March 2010 is in Phase III clinical trials.[1][2][3] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.[1]

Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).[1][4] It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.[1][4] Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.[4][5]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Further reading


  1. 1.0 1.1 1.2 1.3 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. "Search of: pardoprunox - List Results - ClinicalTrials.gov". 
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. 4.0 4.1 4.2 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.